Key result
Standardized vascular health checks prevent up to ~17 MACE per 1000 people screened over 30 years.
Why the study?
No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease.
Do standardized vascular disease health checks improve clinical outcomes and cost-effectiveness in European adults aged 40-75 without known vascular disease?
Do standardized vascular disease health checks improve clinical outcomes and cost-effectiveness in European adults aged 40-75 without known vascular disease?
Effect estimate: 6-17 events prevented per 1000 people screened
p-value: p=<0.0001
A simulated standardized vascular disease health check program in six European countries was projected to reduce cardiovascular and microvascular events and be cost-effective over 30 years.
Model-based estimates suggest health checks may be cost-effective in select European countries; leaves open need for RCTs to confirm value.
BACKGROUND: No clinical trials have assessed the effects or cost-effectiveness of health check strategies to detect and manage vascular disease. We used a mathematical model to estimate the cost-effectiveness of several health check strategies in six European countries. METHODS: We used country-specific data from Denmark, France, Germany, Italy, Poland, and the United Kingdom to generate simulated populations of individuals aged 40-75 eligible for health checks in those countries (e.g. individuals without a previous diagnosis of diabetes, myocardial infarction, stroke, or serious chronic kidney disease). For each country, we used the Archimedes model to compare seven health check strategies consisting of assessments for diabetes, hypertension, lipids, and smoking. For patients diagnosed with vascular disease, treatment was simulated in a standard manner. We calculated the effects of each strategy on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular complications in addition to quality of life, costs, and cost per quality-adjusted life-year (QALY). RESULTS: Compared with current care, health checks reduced the incidence of MACE (6-17 events prevented per 1000 people screened) and diabetes related microvasular complications (5-11 events prevented per 1000 people screened), and increased QALYs (31-59 discounted QALYs) over 30 years, in all countries. The cost per QALY of offering a health check to all individuals in the study cohort ranged from €14903 (France) to cost saving (Poland). Pre-screening the population and offering health checks only to higher risk individuals lowered the cost per QALY. Pre-screening on the basis of obesity had a cost per QALY of €10200 (France) or less, and pre-screening with a non-invasive risk score was similar. CONCLUSIONS: A vascular disease health check would likely be cost effective at 30 years in Denmark, France, Germany, Italy, Poland, and the United Kingdom.
No takes yet. Share an insight, caveat, or question.
Schuetz et al. (2013) studied Vascular disease (diabetes, cardiovascular disease) (n=149,729). Standardized vascular disease health check vs. Current care (no health checks) was evaluated on Incidence of major adverse cardiovascular events (MACE) (6-17 events prevented per 1000 people screened, p=<0.0001). A standardized vascular disease health check reduced the 30-year incidence of major adverse cardiovascular events by 6 to 17 events per 1000 people screened and was cost-effective across six European countries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: